TISIDB

Summary
Symbol	UTRN
Name	utrophin
Aliases	DMDL; utrophin (homologous to dystrophin); dystrophin-related protein 1
Chromosomal Location	6q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cell junction, synapse, postsynaptic cell membrane; Peripheral membrane protein; Cytoplasmic side. Cytoplasm, cytoskeleton. Note=Neuromuscular junction.
Domain	PF00307 Calponin homology (CH) domain PF09068 EF hand PF09069 EF-hand PF00435 Spectrin repeat PF00397 WW domain PF00569 Zinc finger
Function	May play a role in anchoring the cytoskeleton to the plasma membrane.

> Gene Ontology [ TOP ]
Biological Process	GO:0001952 regulation of cell-matrix adhesion GO:0001954 positive regulation of cell-matrix adhesion GO:0002028 regulation of sodium ion transport GO:0003012 muscle system process GO:0006814 sodium ion transport GO:0006936 muscle contraction GO:0007160 cell-matrix adhesion GO:0007517 muscle organ development GO:0007528 neuromuscular junction development GO:0010810 regulation of cell-substrate adhesion GO:0010811 positive regulation of cell-substrate adhesion GO:0010959 regulation of metal ion transport GO:0015672 monovalent inorganic cation transport GO:0022898 regulation of transmembrane transporter activity GO:0031589 cell-substrate adhesion GO:0032409 regulation of transporter activity GO:0032412 regulation of ion transmembrane transporter activity GO:0034762 regulation of transmembrane transport GO:0034765 regulation of ion transmembrane transport GO:0035725 sodium ion transmembrane transport GO:0045785 positive regulation of cell adhesion GO:0050808 synapse organization GO:1902305 regulation of sodium ion transmembrane transport GO:1904062 regulation of cation transmembrane transport GO:2000649 regulation of sodium ion transmembrane transporter activity
Molecular Function	GO:0003779 actin binding GO:0005178 integrin binding GO:0017166 vinculin binding GO:0050839 cell adhesion molecule binding GO:0051015 actin filament binding
Cellular Component	GO:0005938 cell cortex GO:0015629 actin cytoskeleton GO:0016010 dystrophin-associated glycoprotein complex GO:0030175 filopodium GO:0030426 growth cone GO:0030427 site of polarized growth GO:0030863 cortical cytoskeleton GO:0030864 cortical actin cytoskeleton GO:0031253 cell projection membrane GO:0031527 filopodium membrane GO:0031594 neuromuscular junction GO:0042383 sarcolemma GO:0044448 cell cortex part GO:0045211 postsynaptic membrane GO:0070938 contractile ring GO:0090665 glycoprotein complex GO:0097060 synaptic membrane GO:0098794 postsynapse GO:0098858 actin-based cell projection GO:0099568 cytoplasmic region

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	UTRN
Name	utrophin
Aliases	DMDL; utrophin (homologous to dystrophin); dystrophin-related protein 1
Chromosomal Location	6q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between UTRN and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	UTRN
Name	utrophin
Aliases	DMDL; utrophin (homologous to dystrophin); dystrophin-related protein 1
Chromosomal Location	6q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of UTRN in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	UTRN
Name	utrophin
Aliases	DMDL; utrophin (homologous to dystrophin); dystrophin-related protein 1
Chromosomal Location	6q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of UTRN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.119	0.751
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.178	0.907
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.067	0.947
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.18	0.629
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.185	0.952
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.641	0.871
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.529	0.252
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.45	0.809
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.638	0.757
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.545	0.681
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.777	0.33
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.27	0.0143

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of UTRN in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	8.2	6.6	0.452
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	8.5	6.3	0.453
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	33.3	0	33.3	0.0108
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	37.5	0	37.5	0.209
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	30.8	0	30.8	0.0983
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	12.5	-1.4	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	14.3	10.7	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	7.4	-4.8	0.565
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	14.3	-14.3	0.209
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	UTRN
Name	utrophin
Aliases	DMDL; utrophin (homologous to dystrophin); dystrophin-related protein 1
Chromosomal Location	6q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of UTRN. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	UTRN
Name	utrophin
Aliases	DMDL; utrophin (homologous to dystrophin); dystrophin-related protein 1
Chromosomal Location	6q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of UTRN. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by UTRN. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	UTRN
Name	utrophin
Aliases	DMDL; utrophin (homologous to dystrophin); dystrophin-related protein 1
Chromosomal Location	6q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of UTRN. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	UTRN
Name	utrophin
Aliases	DMDL; utrophin (homologous to dystrophin); dystrophin-related protein 1
Chromosomal Location	6q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of UTRN expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	UTRN
Name	utrophin
Aliases	DMDL; utrophin (homologous to dystrophin); dystrophin-related protein 1
Chromosomal Location	6q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between UTRN and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	UTRN
Name	utrophin
Aliases	DMDL; utrophin (homologous to dystrophin); dystrophin-related protein 1
Chromosomal Location	6q24
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting UTRN collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting UTRN.

ID	Name	Drug Type	Targets	#Targets
DB01593	Zinc	Small Molecule	A1BG, A2M, AGT, AHSG, ALDOA, APCS, APLP1, APLP2, APOA1, APOA2, APO ......	119

Browse UTRN